Minimally invasive system for faster, simpler and cheaper detection of breast cancer metastasis

  • Montserrat from Knowledge Innovation Market
  • From Spain
  • Responsive
  • Innovative Products and Technologies

Summary of the technology

HYPOSENS technology is a unique all optical cancer prognostic system that determines specifically the presence of cancer cells in the breast lymph nodes, which indicates cancer metastasis and thus a bad prognosis. This tool will be extremely useful for patient stratification and will represent a significant decrease in the diagnostic costs and an increase in the welfare of patients.

We are looking for collaborators/funding to further validate the technology at clinical level.

Knowledge Innovation Market

Details of the Technology Offer

HYPOSENS technology is a unique all optical cancer prognostic system that determines specifically the presence of cancer cells in the breast lymph nodes, which indicates cancer metastasis and thus a bad prognosis. This tool will be extremely useful for patient stratification and will represent a significant decrease in the diagnostic costs and an increase in the welfare of patients.

Benefits:

LABEL-FREE:The photonics system uses tumour targeted nano-confined sensors for intracellular
temperature and oxygen sensing.
MINIMALLY INVASIVE: It does not require surgery to test the lymph node status.
FAST: Produces results in real-time.
ACCURATE:The nano-confined sensor particles is able to monitor both temperature and dissolved oxygen. Coupling the nano-sensors with target antigens ensures the proper identification of the targeted tumour cells.
SAFE:The prognosis system does not release any ionising radiation.
SIMPLE:The device incorporates a “plug & play” architecture which render it easy to operate.
AFFORDABLE: Due to the compact nature of the imaging system, the development this technology results in a decrease in the diagnostic costs associated with metastatic breast cancer.

Applications:

This imaging system is strategically designed to offer a minimally invasive alternative to the SLNB process. With an approximate cost of €60,000 per device unit and additional €5,500 per patient, the device is an affordable, accurate, easy to use prognostic solution for clinicians, which intends to offer a real time diagnosis of breast cancer metastasis.Although the technology is initially designed for detecting breast cancer cells, it could be potentially adapted for other cancers in which practitioners also employ SLNB as the current prognosis test (e.g. vulval, colorectal and gastric cancer, pelvic and renal tumours), via the use of different tumour-targeting moieties.This technology is, for the moment, a secret know-how.

The technology is now being tested in relevant industrial environments (TRL5) and it is available for demonstration.

Opportunities:

We are looking for any private or public funding opportunity to further develop the HYPOSENS diagnostic imaging device to further validate the technology in vivo and clinically before it represents a market reality for improving patient’s health. Hospital collaborations will be appreciated too.

Intellectual property status

Other forms of protection

Current development status

Laboratory prototypes

Attached documents

Related Keywords

  • Applications for Health
  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Detection and Analysis methods
  • Measurements and Standards
  • Measurement Tools
  • Analyses / Test Facilities and Methods
  • Medical/health
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Medical imaging
  • Other ( Diagnostic related )
  • Other Medical/Health Related
  • Clinical Medicine
  • Oncology
  • Medical equipment
  • Electromedical and medical equipment
  • Medical instruments
  • Diagnostic equipment
  • antibody
  • photonics
  • breast cancer

About Knowledge Innovation Market

KIM aligns industry expectations and research and technology centers to explore Open Innovation opportunities

Expertise. We have been practicing Open Innovation (Tech Transfer) between industry and research and technological centers since 2007.
PULL Philosophy. The driver that guides our activity with RTOs is to respond to the needs of our industrial customers, mostly large multinational companies.
360º vision. We have a technological vision of the processes of acquisition and commercialization of early stage technologies and other assets of IP (know how, patents …), but also of business, financial, legal and IP models …
Cross innovation. We have a horizontal knowledge of the market, which allows us to reposition and transfer technologies from one industry to another.
Facilitators. We have extensive experience in national and international transfer finance instruments. This allows us to be able to connect public and private instruments.
We have offices in Barcelona, Madrid, Vigo and Santiago de Chile. And we are in The Knowledge Agents Alliance (KAA), an international network of knowledge transfer agents.

Montserrat Sole Castellvi

Never miss an update from Montserrat Sole Castellvi

Create your free account to connect with Montserrat Sole Castellvi and thousands of other innovative organizations and professionals worldwide

Montserrat

Send a request for information
to Montserrat

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support